Conformation-specific inhibitors of Raf kinases.

Research paper by Xiaolun X Wang, Kristin K Schleicher

Indexed on: 01 Jan '13Published on: 01 Jan '13Published in: The Enzymes


Since the discovery linking B-Raf mutations to human tumors in 2002, significant advances in the development of Raf inhibitors have been made, leading to the recent approval of two Raf inhibitor drugs. This chapter includes a brief introduction to B-Raf as a validated target and focuses on the three different binding modes observed with Raf small-molecule inhibitors. These various binding modes lock the Raf kinase in different conformations that impact the toxicity profiles of the inhibitors. Possible solutions to mitigate the side effects caused by inhibitor-induced dimerization are also discussed.